Romiplostim, a fusion protein analog of thrombopoietin [51] and eltrombopag, a thrombopoietin receptor agonist [60], are both FDA approved for the treatment or prevention of various platelet disorders and may be effective in this role. This evidence concerns the gene MPL and blood platelet disease.